-
Color Genomics Raises $45 Million To Expand Genetic Testing
Bloomberg | Color Genomics Inc., the three-year-old startup aiming to democratize genetic testing, sealed $45 million in funding as it seeks to make its tests for cancer more affordable and accessible, the company announced Tuesday.
Sep 27, 2016
-
Kite Unveils Anticipated CAR-T Cancer Data Positive But Not Complete
Xconomy | Kite Pharma has dipped into a highly anticipated clinical trial of its cancer treatment, KTE-C19, to release a partial set of data. Although not complete, the data bolster the view that Kite could be the first among its peers to win the FDA's green light.
Sep 27, 2016
-
The Sequencing App and the Quest for Fun
Bio-IT World | The latest way to get into your genome is a $50 app-based venture that promises to give you a peek into your ancestry and tell you what kinds of bacteria you’re harboring in your mouth. Seeq launched earlier this month offering ultra-low coverage sequencing of the genome, oral microbiome sequencing, and ancestry reports. The goal is an extremely inexpensive infrastructure for people to get a little bit of genomic data and participate in research in a way that’s easy and fun.
Sep 26, 2016
-
Top Scientists Cautious About Curing Cancer With Immunotherapy
STAT | There's been a lot of excitement about immunotherapy as a tool to treat cancer. But top experts on Sunday struck an unexpected note of caution.
Sep 26, 2016
-
New Genomics Pipeline Combines AWS, Local HPC, and Supercomputing
HPCwire | Declining DNA sequencing costs and the rush to do whole genome sequencing (WGS) of large cohort populations presents an infrastructure challenge that some researchers are solving with a hybrid approach.
Sep 23, 2016
-
When “Actionable” Genomic Sequencing Results Cannot Be Acted Upon
JAMA Oncology | Brian J. Zikmund-Fisher recounts an interaction he had with a participant involved in genomic sequencing, in which the term “actionable” led to false hope and dashed expectations.
Sep 23, 2016
-
Gilead Allergan Seen Trailing Intercept In Ongoing NASH Battle
Investor's Business Daily | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in.
Sep 23, 2016


